Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ARG1 | P05089 | 1/20 | 0.48 |
| ▸ | ARG2 | P78540 | 1/20 | 0.48 |
| ▸ | NOS2 | P35228 | 3/20 | 0.43 |
| ▸ | NOS1 | P29475 | 2/20 | 0.43 |
| ▸ | NOS3 | P29474 | 1/20 | 0.43 |
| ▸ | SLC1A1 | P43005 | 2/20 | 0.42 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.38 |
| ▸ | SLC7A11 | Q9UPY5 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.37 |
| ▸ | USP2 | O75604 | 1/20 | 0.36 |
| ▸ | SLCO1B1 | Q9Y6L6 | 1/20 | 0.36 |
| ▸ | BHMT | Q93088 | 3/20 | 0.36 |
| ▸ | OR51E2 | Q9H255 | 1/20 | 0.36 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.35 |
| ▸ | GRM8 | O00222 | 1/20 | 0.35 |
| ▸ | GRM6 | O15303 | 1/20 | 0.35 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.35 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.35 |
| ▸ | GSR | P00390 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1275073 | 1.00 | ARG1 (0.48) | ARG1ARG2NOS2NOS1NOS3 | |
| SCHEMBL788420 | 1.00 | ARG1 (0.48) | ARG1ARG2NOS2NOS1NOS3 | |
| SCHEMBL28438779 | 0.88 | ARG1 (0.40) | ARG1ARG2NOS2NOS1NOS3 | |
| SCHEMBL28438780 | 0.88 | ARG1 (0.40) | ARG1ARG2NOS2NOS1NOS3 | |
| SCHEMBL36935 | 0.84 | ARG1 (0.61) | ARG1ARG2NOS2NOS1NOS3 | |
| SCHEMBL36933 | 0.84 | ARG1 (0.61) | ARG1ARG2NOS2NOS1NOS3 | |
| SCHEMBL29378137 | 0.84 | ARG1 (0.61) | ARG1ARG2NOS2NOS1NOS3 | |
| SCHEMBL29393779 | 0.84 | ARG1 (0.61) | ARG1ARG2NOS2NOS1NOS3 | |
| SCHEMBL36934 | 0.84 | ARG1 (0.61) | ARG1ARG2NOS2NOS1NOS3 | |
| SCHEMBL27218111 | 0.82 | ARG1 (0.53) | ARG1ARG2NOS2NOS1NOS3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 202 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160184404-A1 | NOVEL HEMOGLOBIN-DERIVED PEPTIDE BASED PHARMACEUTICAL COMPOSITIONS | CLINIQUE LA PRAIRIE (CH) | 2016-06-30 | — | — | US | claimed |
| EP-2983698-A1 | NOVEL HEMOGLOBIN-DERIVED PEPTIDE BASED PHARMACEUTICAL COMPOSITIONS | Clinique La Prairie (CH) | 2016-02-17 | — | — | EP | claimed |
| CN-105283200-A | Novel pharmaceutical compositions based on hemoglobin-derived peptides | CLINIQUE LA PRAIRIE | 2016-01-27 | — | — | CN | claimed |
| WO-2014167091-A1 | NOVEL HEMOGLOBIN-DERIVED PEPTIDE BASED PHARMACEUTICAL COMPOSITIONS | CLINIQUE LA PRAIRIE (CH) | 2014-10-16 | — | — | WO | claimed |
| EP-2789343-A1 | Novel hemoglobin-derived peptide based pharmaceutical compositions | Clinique La Prairie (CH) | 2014-10-15 | — | — | EP | claimed |
| US-20130178412-A1 | DIHYDROXYPROPLY-CYSTEINE PEPTIDE AND AGENT CONTAINING THIS PEPTIDE | MUEHLRADT PETER F (DE) | 2013-07-11 | — | — | US | claimed |
| US-7435790-B2 | Dihydroxypropyl cysteine peptide and agent containing this peptide | HELMHOLTZ-ZENTRUM FUER INFEKTIONSFORSCHUNG GMBH (DE) | 2008-10-14 | — | — | US | claimed |
| EP-0946590-B1 | DIHYDROXYPROPYL CYSTEINE PEPTIDE AND AGENT CONTAINING THIS PEPTIDE | BIOTECHNOLOGISCHEFORSCHUNG MBH (DE) | 2004-03-17 | — | — | EP | claimed |
| US-20030220265-A1 | Dihydroxypropyl cysteine peptide and agent containing this peptide | MUEHLRADT PETER F (DE) | 2003-11-27 | — | — | US | claimed |
| US-6573242-B1 | Composition for activating macrophages comprising S-(2,3-dihydroxypropyl)-cysteine peptide having two fatty acids bonded as esters to dihydroxypropyl group and having specified amino acid sequence | GESELLSCHAFT FUER BIOTECHNOLOGISCHE (DE) | 2003-06-03 | — | — | US | claimed |
| EP-4633643-A1 | USE OF BORON FOR THE TREATMENT OF LEISHMANIASIS DISEASE OF NEURONAL ORIGIN | Yeditepe Universitesi (TR) | 2025-10-22 | — | — | EP | disclosed |
| EP-4633617-A1 | USE OF BORON FOR THE TREATMENT OF LEISHMANIASIS DISEASE | Yeditepe Universitesi (TR) | 2025-10-22 | — | — | EP | disclosed |
| EP-3728289-B1 | OPTIMISED COMPOUNDS | Axelia Oncology Pty Ltd (AU) | 2025-09-10 | — | — | EP | disclosed |
| US-20250066416-A1 | OPTIMISED COMPOUNDS | THE UNIVERSITY OF MELBOURNE (AU) | 2025-02-27 | — | — | US | disclosed |
| US-12234263-B2 | Influenza vaccines | INVVAX, INC. (US) | 2025-02-25 | — | — | US | disclosed |
| EP-0114787-A2 | Peptide derivatives | CIBA-GEIGY AG (CH) | 1984-08-01 | — | — | EP | disclosed |
| US-4139635-A | Cysteamine derivatives for oral treatment of seborrhea | L'OREAL (FR) | 1979-02-13 | — | — | US | disclosed |
| US-4085217-A | DERIVATIVES OF CYSTEINE OR CYSTEAMINE | L'OREAL (FR) | 1978-04-18 | — | — | US | disclosed |
| US-4035492-A | Oral treatment of seborrhea with cysteamine derivatives | L'OREAL (FR) | 1977-07-12 | — | — | US | disclosed |
| US-3950542-A | Cysteamine derivatives for oral treatment of seborrhea | L'OREAL (FR) | 1976-04-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250066416-A1 | OPTIMISED COMPOUNDS | TLR2, TLR3, TLR1 | ARG1 2371/4885ARG2 1535/4885NOS2 3526/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.